axitinib,pembrolizumab
pfizer,merck
['keynote-426', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)']
pfs2 analysis for keynote-426 in 1l mrcc: pfs2 improved for pembro + axi vs sun in: itt pop: 40.1 m vs 27.7 m (hr 0.63, 95% ci 0.53-0.75) imdc fav: 46.0 m vs 39.9 m (hr 0.68, 95% ci 0.47-0.98) imdc int/poor: 32.1 m vs 20.1 m (hr 0.62, 95% ci 0.51-0.76) #asco22 
Uro Onc @GACancerCenter | Res PD & Ronald W. Lewis MD Chair of Uro Educ @mcg_urology | Digital Media Ed @EUplatinum | #mentalhealth research | @urotoday